Cardiometabolic Health Congress

JULY 25, 2023

Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiology Update

APRIL 9, 2024

STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes. Investigators randomized 616 adult patients with HFpEF and obesity to receive either once weekly semaglutide (n=310) or placebo (n=306).

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59